Outlook Therapeutics
OTLK
63 hedge funds and large institutions have $8.64M invested in Outlook Therapeutics in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 10 closing their positions.
131% more call options, than puts
Call options by funds: $74K | Put options by funds: $32K
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
3.47% more ownership
Funds ownership: 18.25% → 21.72% (+3.5%)
3% more funds holding
Funds holding: 61 → 63 (+2)
1% more capital invested
Capital invested by funds: $8.59M → $8.64M (+$57.3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.72M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.5M |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$642K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$381K |
| 5 |
BlackRock
New York
|
+$261K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$337K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$301K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$286K |
| 4 |
Renaissance Technologies
New York
|
-$246K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$190K |
OTLK Hedge Fund Activity: Q1 2025 in Review
63 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2025, worth a combined $8.64M — up 0.67% from $8.59M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new OTLK positions and 10 closed out — a net gain of 2 holders — while 24 added to existing stakes and 14 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $2.72M. The largest seller was UBS Group, cutting an estimated $337K.
- 63 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2025, up from 61 in Q4 2024.
- Funds reported $8.64M of Outlook Therapeutics stock for Q1 2025, up 0.67% quarter-over-quarter.
- 12 funds opened new Outlook Therapeutics positions in Q1 2025 and 10 closed out, a net change of +2 holders.
- The largest Outlook Therapeutics buyer in Q1 2025 was Schonfeld Strategic Advisors, an estimated $2.72M added.
- The largest Outlook Therapeutics seller in Q1 2025 was UBS Group, an estimated $337K sold.
Based on aggregated 13F filings for Q1 2025.